Carfilzomib Impurity 13 HCl, with the CAS number 1396006-45-3, is a chemical compound associated with the pharmaceutical agent Carfilzomib, which is used primarily in the treatment of multiple myeloma. As an impurity, it may arise during the synthesis or formulation of Carfilzomib and can impact the drug's efficacy and safety profile. The compound is characterized by its hydrochloride salt form, which typically enhances solubility in aqueous solutions, making it relevant for pharmaceutical applications. Its molecular structure includes specific functional groups that may influence its reactivity and interaction with biological systems. Impurities like Carfilzomib Impurity 13 HCl are often monitored for quality control in drug manufacturing to ensure compliance with regulatory standards. Understanding the characteristics of such impurities is crucial for assessing their potential effects on drug performance and patient safety. Analytical techniques such as HPLC and mass spectrometry are commonly employed to identify and quantify impurities in pharmaceutical products.

Carfilzomib Impurity 13 HCl

1396006-45-3: Carfilzomib Impurity 13 HCl, with the CAS number 1396006-45-3, is a chemical compound associated with the pharmaceutical agent Carfilzomib, which is used primarily in the treatment of multiple myeloma. As an impurity, it may arise during the synthesis or formulation of Carfilzomib and can impact the drug's efficacy and safety profile. The compound is characterized by its hydrochloride salt form, which typically enhances solubility in aqueous solutions, making it relevant for pharmaceutical applications. Its molecular structure includes specific functional groups that may influence its reactivity and interaction with biological systems. Impurities like Carfilzomib Impurity 13 HCl are often monitored for quality control in drug manufacturing to ensure compliance with regulatory standards. Understanding the characteristics of such impurities is crucial for assessing their potential effects on drug performance and patient safety. Analytical techniques such as HPLC and mass spectrometry are commonly employed to identify and quantify impurities in pharmaceutical products.

CAS 1396006-45-3

Carfilzomib Impurity 13 HCl

Carfilzomib Impurity 13 (PR-389/M14)

Ref: 4Z-C-121083

Carfilzomib Impurity 13 HCl

Ref: 4Z-C-121016

Carfilzomib Impurity 13

Ref: ST-EA-CP-C153022